{"id":6729,"date":"2021-03-16T15:47:06","date_gmt":"2021-03-16T22:47:06","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6729"},"modified":"2021-03-17T16:10:38","modified_gmt":"2021-03-17T23:10:38","slug":"covid-19-literature-situation-report-mar-16-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/16\/covid-19-literature-situation-report-mar-16-2021\/","title":{"rendered":"COVID-19 Literature Situation Report Mar 16, 2021"},"content":{"rendered":"<p>The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n<p><em>Today&#8217;s summary is based on a review of 529 articles (514 published, 15 in preprint)<\/em><\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><b>Only 17% (76 of 436) of solid organ transplant recipients developed detectable antibody responses at a median of 20 days after the first dose of either the Moderna or Pfizer-BioNTech vaccines, according to a convenience sample of US patients. Transplant recipients who were receiving immunosuppression therapy, older transplant recipients, and those vaccinated with the Pfizer-BioNTech vaccine (as compared to the Moderna vaccine) were less likely to develop detectable antibody responses.<\/b> <a href=\"https:\/\/doi.org\/10.1001\/jama.2021.4385\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>The SARS-CoV-2 P.1 variant which has caused large outbreaks in Brazil is less resistant to neutralization from both convalescent serum and vaccine-induced serum than the B.1.351 variant originally identified in South Africa, despite containing similar receptor binding domain mutations (E484K, K417N\/T and N501Y). <\/b><a href=\"https:\/\/doi.org\/10.1101\/2021.03.12.435194\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<\/ul>\n<div id=\"uw-accordion-shortcode\">\n<h3>Article Summaries<\/h3>\n<div class=\"js-accordion\" data-accordion-prefix-classes=\"uw-accordion-shortcode\">\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Non-Pharmaceutical Interventions<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-6732\" class=\"su-post\">\n<h5 class=\"su-post-title\">Social Distancing Compliance: A Video Observational Analysis<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Closed Circuit Television (CCTV) footage in inner-city Amsterdam, Netherlands showed short-lived adherence to physical distancing measures following implementation of \u201clockdown\u201d policies. From February to May 2020, the observed number of physical distancing violations (less than 1.5 meters) decreased following announcements of physical distancing measures and full lockdown on March 23rd, but then increased onwards from April 2 until the end of the observation period.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Hoeben et al.\u00a0(Mar 15, 2021). Social Distancing Compliance: A Video Observational Analysis. PLOS ONE. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1371\/journal.pone.0248221\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1371\/journal.pone.0248221<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6730\" class=\"su-post\">\n<h5 class=\"su-post-title\">Early Public Adherence with and Support for Stay-at-Home COVID-19 Mitigation Strategies despite Adverse Life Impact: A Transnational Cross-Sectional Survey Study in the United States and Australia<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Self-reported adherence to COVID-19 mitigation policies was high in both highly- and minimally-affected regions in the US around the time of the first wave in April 2020, according to representative cross-sectional surveys (n=5,573) administered to adults residing in throughout the US, in New York City and Los Angeles, and Australia. 82% reported adherence to recommended quarantine and stay-at-home policies, and 90% supported government-imposed measures.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Czeisler et al.\u00a0(Mar 15, 2021). Early Public Adherence with and Support for Stay-at-Home COVID-19 Mitigation Strategies despite Adverse Life Impact: A Transnational Cross-Sectional Survey Study in the United States and Australia. BMC Public Health. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1186\/s12889-021-10410-x\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1186\/s12889-021-10410-x<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Vaccines and Immunity<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-6742\" class=\"su-post\">\n<h5 class=\"su-post-title\">Reinfection Rates among Patients Who Previously Tested Positive for COVID-19: A Retrospective Cohort Study<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Previous SARS-COV-2 infection was associated with a lower likelihood of subsequent reinfection compared to those without a previous history of infection. These results are based on a cohort study of over 150,000 patients from a multi-hospital system in Ohio and Florida. Among 8,845 initially PCR-positive patients, 1,278 were retested after \u226590 days and 62 (0.4%) had reinfection (CDC definition of reinfection is a positive test \u226590 days after initial positive test). Of 141,480 initially PCR-negative patients, 39,487 were retested after \u226590 days and 3,191 (2.3%) had positive results. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: This analysis relies on medical records of SARS-CoV-2 PCR testing and does not represent a random sample of people with and without prior SARS-CoV-2 infection. Differences between those who do and do not retest for SARS-CoV-2 after an initial positive or negative test result could greatly affect the observed test positivity. Conclusions based on these findings about the effectiveness of prior infection against re-infection should be made with great caution.]\u00a0<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Sheehan et al.\u00a0(Mar 15, 2021). Reinfection Rates among Patients Who Previously Tested Positive for COVID-19: A Retrospective Cohort Study. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab234\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab234<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6740\" class=\"su-post\">\n<h5 class=\"su-post-title\">BNT162b2 MRNA COVID-19 Vaccine Induces Antibodies of Broader Cross-Reactivity than Natural Infection but Recognition of Mutant Viruses Is up to 10-Fold Reduced<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Antibodies induced by the Pfizer-BioNTech vaccine had higher binding capacities (avidity) than antibodies induced by natural infection against the receptor binding domain (RBD) containing mutations representative of circulating SARS-CoV-2 variants of concern (N501Y, K417N, E484K, and a combination of all three).\u00a0 Vaccine-induced sera (n=6) reduced binding against the RBD containing the N501Y and K417 mutations (2.5-3 fold reduction) compared to wild type RBD. Of note, both the RBD with E484K mutation and RBD with all three mutations reduced binding by ~10-fold, indicating that E484K mutation (found in the B.1.351 and P.1 variant but not in the B.1.1.7 variant) substantially reduces antibody binding.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Chang et al.\u00a0(Mar 15, 2021). BNT162b2 MRNA COVID-19 Vaccine Induces Antibodies of Broader Cross-Reactivity than Natural Infection but Recognition of Mutant Viruses Is up to 10-Fold Reduced. Pre-print downloaded Mar 16 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.03.13.435222\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.03.13.435222<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6738\" class=\"su-post\">\n<h5 class=\"su-post-title\">Antibody Evasion by the Brazilian P.1 Strain of SARS-CoV-2<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> The SARS-CoV-2 P.1 variant, which has caused large outbreaks in Brazil, is less resistant to neutralization from both convalescent serum and vaccine-induced serum than the B.1.351 variant originally identified in South Africa, despite containing similar receptor binding domain (RBD) mutations (E484K, K417N\/T and N501Y). Similar to the B.1.351 variant, mutations associated with the P1 variant completely abrogated the binding of multiple neutralizing antibodies directed against the RBD, including a variety of antibodies currently in development for therapeutic use. In contrast, the reduction in neutralization activity of convalescent plasma from recovered volunteers against the P.1 variant was only modest (~3-fold reduction versus the ancestral Victoria strain) when compared to the reduction in neutralization observed with B.1.351 variant (~13-fold reduction versus the Victoria strain).\u00a0 Sera from recipients of either the Pfizer-BioNTech or Oxford-Aztrazeneca vaccine had similar modest reductions in neutralization activity (~3-fold) when compared to the reductions in neutralization observed with the B.1.351 variant (~8-9 fold).\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Dejnirattisai et al. Antibody Evasion by the Brazilian P.1 Strain of SARS-CoV-2. Pre-print downloaded Mar 16 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.03.12.435194\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.03.12.435194<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6736\" class=\"su-post\">\n<h5 class=\"su-post-title\">Antibody Response After SARS-CoV-2 Infection and Implications for Immunity<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A review of 66 observational studies found that most adults with SARS-CoV-2 infection develop IgM and IgG antibody responses. Among studies measuring IgM antibody responses (n=21 studies), 80% of adults developed responses, peaking at 20 days. Among studies measuring IgG antibody responses (n=24 studies), 95% of adults developed responses, peaking at 25 days and remaining detectable up to 120 days. Studies evaluating neutralizing responses (n=8 studies) were more varied in methodology, but suggest that 99% develop neutralizing antibodies.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Arkhipova-Jenkins et al.\u00a0(Mar 16, 2021). Antibody Response After SARS-CoV-2 Infection and Implications for Immunity. Annals of Internal Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.7326\/M20-7547\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.7326\/M20-7547<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6734\" class=\"su-post\">\n<h5 class=\"su-post-title\">Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Solid organ transplant recipients in the US were less likely to develop anti-SARS-CoV-2 antibody responses after receiving a single dose of either the Moderna or Pfizer-BioNTech vaccines. In a prospective convenience sample, only 17% (76 of 436) had detectable antibody responses at a median of 20 days after the first dose. Transplant recipients who were receiving immunosuppression therapy, older transplant recipients, and those vaccinated with the Pfizer-BioNTech vaccine (as compared to the Moderna vaccine) were less likely to develop detectable antibody responses.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Boyarsky et al.\u00a0(Mar 15, 2021). Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jama.2021.4385\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jama.2021.4385<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Public Health Policy and Practice<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-6748\" class=\"su-post\">\n<h5 class=\"su-post-title\">Which Beliefs Predict Intention to Get Vaccinated against COVID-19? A Mixed-Methods Reasoned Action Approach Applied to Health Communication<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Key themes that drive COVID-19 vaccination intentions including protecting oneself from COVID-19 infection, protecting those who are at risk for severe illness, and having to travel to receive the vaccine, based on an open-ended belief elicitation survey (n=197) conducted in the US. In a quantitative survey informed by qualitative findings, intent to receive the vaccine was most strongly correlated with &#8216;achieving peace of mind&#8217;, followed by influences from family and friends, and perceived capacity to obtain the vaccine (e.g. traveling to a vaccination site).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Lueck and Spiers. (Mar 13, 2021). Which Beliefs Predict Intention to Get Vaccinated against COVID-19? A Mixed-Methods Reasoned Action Approach Applied to Health Communication. Journal of Health Communication. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1080\/10810730.2020.1865488\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1080\/10810730.2020.1865488<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6746\" class=\"su-post\">\n<h5 class=\"su-post-title\">Self-Reported Hearing Difficulties Are Associated with Loneliness, Depression and Cognitive Dysfunction during the COVID-19 Pandemic<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">In the context of increased social isolation during the COVID-19, hearing difficulties among older adults were associated with self-reported anxiety, depression, and cognitive function, according to an online survey. Participants (n=80) had a mean age of 76 years and had their hearing measured by the Speech, Spatial and Qualities of Hearing Scale (SSQ12) and were asked questions about socialization, loneliness, depression, and self-perceived cognitive function both pre-and-post pandemic. After adjusting for age, gender, and education, the association of hearing difficulty with cognitive function persisted.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Littlejohn et al.\u00a0(Mar 15, 2021). Self-Reported Hearing Difficulties Are Associated with Loneliness, Depression and Cognitive Dysfunction during the COVID-19 Pandemic. International Journal of Audiology. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1080\/14992027.2021.1894492\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1080\/14992027.2021.1894492<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-6744\" class=\"su-post\">\n<h5 class=\"su-post-title\">Association of Preterm Birth Rate With COVID-19 Statewide Stay-at-Home Orders in Tennessee<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The preterm birth rate in Tennessee was lower in 2020 during the stay-at-home order compared with the 5 preceding years. After adjusting for maternal age, education, race\/ethnicity, diabetes, and hypertension the odds for preterm birth in 2020 was 14% lower compared with 2015 to 2019 (10.2% vs 11.3%).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Harvey et al.\u00a0(Mar 15, 2021). Association of Preterm Birth Rate With COVID-19 Statewide Stay-at-Home Orders in Tennessee. JAMA Pediatrics. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jamapediatrics.2020.6512\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jamapediatrics.2020.6512<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Other Resources and Commentaries<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.7717\/peerj.10927\"><span style=\"font-weight: 400\">Publication Rate and Citation Counts for Preprints Released during the COVID-19 Pandemic: The Good, the Bad and the Ugly<\/span><\/a><span style=\"font-weight: 400\"> \u2013 PeerJ (Mar 3)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1001\/jamainternmed.2021.0074\"><span style=\"font-weight: 400\">SARS-CoV-2 Seroprevalence Data to Guide Local Public Health Interventions<\/span><\/a><span style=\"font-weight: 400\"> \u2013 JAMA Internal Medicine (Mar 15)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1136\/bmj.n701\"><span style=\"font-weight: 400\">Children and the Return to School: How Much Should We Worry about Covid-19 and Long Covid<\/span><\/a><span style=\"font-weight: 400\"> \u2013 BMJ (Mar 15)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/S2213-2600(21)00126-0\"><span style=\"font-weight: 400\">Could a Good Night\u2019s Sleep Improve COVID-19 Vaccine Efficacy<\/span><\/a><span style=\"font-weight: 400\"> \u2013 The Lancet Respiratory Medicine (Mar 12)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100780\"><span style=\"font-weight: 400\">Correcting COVID-19 Vaccine Misinformation<\/span><\/a><span style=\"font-weight: 400\"> \u2013 EClinicalMedicine (Mar 6)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.ijedudev.2020.102326\"><span style=\"font-weight: 400\">Modelling the Long-Run Learning Impact of the Covid-19 Learning Shock: Actions to (More than) Mitigate Loss<\/span><\/a><span style=\"font-weight: 400\"> \u2013 International Journal of Educational Development (Dec 18, 2020)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1080\/10810730.2020.1894015\"><span style=\"font-weight: 400\">COVID-19: An Urgent Call for Coordinated, Trusted Sources to Tell Everyone What They Need to Know and Do<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Health Communication (Mar 13)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.2471\/BLT.21.285550\"><span style=\"font-weight: 400\">Coordinating COVID-19 Vaccine Deployment through the WHO COVID-19 Partners Platform<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Bulletin of the World Health Organization (Mar 1)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.2471\/BLT.21.020321\"><span style=\"font-weight: 400\">COVID-19 Vaccines: Resolving Deployment Challenges<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Bulletin of the World Health Organization (Mar 1)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.2196\/26780\"><span style=\"font-weight: 400\">Public Discourse Against Masks in the COVID-19 Era: Infodemiology Study of Twitter Data (Preprint)<\/span><\/a><span style=\"font-weight: 400\"> \u2013 <\/span><span style=\"font-weight: 400\">JMIR Public Health and Surveillance (Mar 16, 2021)<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Only 17% (76 of 436) of solid organ transplant recipients developed detectable antibody responses at a median of 20 days after the first dose of either the Moderna or Pfizer-BioNTech vaccines, according to a convenience sample of US patients. Transplant recipients who were receiving immunosuppression therapy, older transplant recipients, and those vaccinated with the Pfizer-BioNTech vaccine (as compared to the Moderna vaccine) were less likely to develop detectable antibody responses. <\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/16\/association-of-preterm-birth-rate-with-covid-19-statewide-stay-at-home-orders-in-tennessee\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":5840,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[5],"tags":[],"topic":[],"class_list":["post-6729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-literature-situation-report"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6729"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6729\/revisions"}],"predecessor-version":[{"id":6751,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6729\/revisions\/6751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media\/5840"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6729"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}